Nebenwirkungen · Libtayo
LIBTAYO 350 mg concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 15
HOS-142320 · Präparat HOS-098800
Immune-mediated endocrinopathies Hypothyroidism occurred in 87 (6.8%) of 1281 patients receiving cemiplimab, including 1 (< 0.1%) patient with Grade 3 hypothyroidism. Three (0.2%) of 1281 patients discontinued cemiplimab due to hypothyroidism. Among the 87 patients with hypothyroidism, the median time to onset was 4.0 months (range: 15 days to 18.9 months) with a median duration of 9.2 months (range: 1 day to 37.1 months). Resolution of hypothyroidism had occurred in 5 (5.7%) of the 87 patients at the time of data cutoff.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-10T09:43:00Z · SHA-256 e26a4d46dee107273416cff167125ea4a2d57ae4635bf68f860ceb24b87bd4b6 · Passage 6445192e30580fdfc8e173b9759af6ce92a57da93d7d82f8b8214a6755475529 · Zeichen 18428–18955 im Abschnitt